- Conditions
- Alzheimer's Disease, Dementia
- Interventions
- Drug: EVP-6124, Placebo
- Drug
- Lead sponsor
- FORUM Pharmaceuticals Inc
- Industry
- Eligibility
- 55 Years to 85 Years
- Enrollment
- 403 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 42
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Culver City, California + 39 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1273–1296
of 1,667
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Hodgkin Lymphoma
- Interventions
- Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy, Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 19 more
- Conditions
- Hereditary Inclusion Body Myopathy (HIBM)
- Interventions
- Sialic Acid Extended Release (SA-ER) Tablets, Sialic Acid Extended Release (SA-ER) Tables
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Costa Mesa, California • New York, New York
- Conditions
- Breast Cancer, Thyroid Cancer
- Interventions
- Definity, Acoustic Angiography
- Drug · Device
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Pneumonia, Pneumocystis Carinii, HIV Infections
- Interventions
- Trimetrexate glucuronate, Methylprednisolone, Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Leucovorin calcium
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1989
- U.S. locations
- 1
- States / cities
- West Columbia, South Carolina
- Conditions
- High-Grade Glioma (WHO III-IV)
- Interventions
- FG001
- Drug
- Lead sponsor
- FluoGuide A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Miami, Florida • Lebanon, New Hampshire • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Osteoarthritis
- Interventions
- SD-6010, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 40 Years to 99 Years
- Enrollment
- 1,457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 120
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 83 more
- Conditions
- Hematopoietic Stem Cell Transplantation, Graft Failure
- Interventions
- Emapalumab 3 mg/kg, Emapalumab 10 mg/kg
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Selected Advanced Solid Tumors, Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Cancer (BTC), Gastric Cancer (GC), Esophageal Cancer (EC), Head and Neck Squamous Cell Cancer (HNSCC)
- Interventions
- SKL35501, SKL35502
- Drug · Diagnostic Test
- Lead sponsor
- SK Life Science, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 2
- States / cities
- Glen Burnie, Maryland • Pittsburgh, Pennsylvania
- Conditions
- Myeloid Malignancy, Acute Myeloid Leukemia
- Interventions
- Venetoclax, Decitabine
- Drug
- Lead sponsor
- Benjamin Tomlinson
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Interventions
- BAL0891, Tislelizumab, Paclitaxel
- Drug · Combination Product
- Lead sponsor
- SillaJen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
- Conditions
- Heart Failure; With Decompensation
- Interventions
- Bumetanide, Furosemide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Thyroid Eye Disease, Graves Orbitopathy, Endocrine System Diseases, Eye Diseases, Thyroid Associated Ophthalmopathy, Graves Ophthalmopathy, Thyroid Diseases, Orbital Diseases, Proptosis, IGF1R, Exophthalmos, Hashimoto
- Interventions
- Linsitinib, Placebo
- Drug
- Lead sponsor
- Sling Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 19
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 15 more
- Conditions
- Cytomegalovirus Infections, Solid Organ Transplant
- Interventions
- CMV specific T-cells
- Biological
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Age-Related Osteoporosis
- Interventions
- Teriparatide, Alendronate
- Drug
- Lead sponsor
- Madhumathi Rao
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- COVID-19
- Interventions
- RBT-9 (90 mg), 0.9% sodium chloride (normal saline)
- Drug
- Lead sponsor
- Renibus Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 5
- States / cities
- New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Inclisiran, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years to 11 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri + 1 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- ADZENYS XR-ODT, Placebo Oral Tablet
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 5 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- Crohn's Disease (CD)
- Interventions
- Vedolizumab IV
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Interventions
- Atezolizumab, Biopsy Procedure, Biospecimen Collection, Cetuximab, Cisplatin, Computed Tomography, Docetaxel, Intensity-Modulated Radiation Therapy, Magnetic Resonance Imaging, Survey Administration
- Drug · Procedure · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 613 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2027
- U.S. locations
- 338
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 266 more
- Conditions
- Healthy, MDMA ('Ecstasy')
- Interventions
- 3,4-Methylenedioxymethamphetamine, methamphetamine
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Vitiligo
- Interventions
- Rapamycin, Placebo
- Drug
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 13 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Interventions
- bleomycin sulfate, amifostine trihydrate, cisplatin, etoposide, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 14 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more
- Conditions
- Progressive IgA Nephropathy, Proteinuria
- Interventions
- ACTH (Acthar) Gel
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more